Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body to transform the treatment of cancer. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) is designed to harness the body’s intrinsic immune system without the need for ex vivo manipulation.
Cue Biopharma’s off-the-shelf biologics are designed to mimic the natural signals, or “Cues,” of the immune system. Our biologics address the specificity and diversity of the human immune system to cure disease by activating tumor-specific T cells directly in the patient’s body to attack only cancer cells. Immuno-STATs have the potential to provide the patient with a more effective response while preserving safety, by avoiding the systemic and indiscriminate immune activation of available immune-modulating drugs that can often lead to severe adverse events, dose-limiting toxicities, treatment discontinuation, and inadequate efficacy.
Headquartered in Boston, Massachusetts, the company is led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.
Oct 05 | 2022
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
Oct 04 | 2022